About: Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms
Creator	Zhou, Zhiqiang Li, Shiyong Zhao, · Kang, Huicong
Source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19), a disease caused by the novel betacoronavirus (SARS-CoV-2), has become a global pandemic threat. The potential involvement of COVID-19 in central nervous system (CNS) has attracted considerable attention due to neurological manifestations presented throughout the disease process. In addition, SARS-CoV-2 is structurally similar to SARS-CoV, and both bind to the angiotensin-converting enzyme 2 (ACE2) receptor to enter human cells. Thus, cells expressing ACE2, such as neurons and glial cells may act as targets and are thus vulnerable to SARS-CoV-2 infection. Here, we have reviewed the neurological characteristics of COVID-19 and summarized possible mechanisms of SARS-CoV-2 invasion of the CNS. COVID-19 patients have presented with a number of different neurological symptoms such as headache, dizziness, hyposmia, and hypogeusia during the course of illness. It has also been reported recently that some cases of COVID-19 have presented with concurrent acute cerebrovascular disease (acute ischemic stroke, cerebral venous sinus thrombosis, cerebral hemorrhage, subarachnoid hemorrhage), meningitis/encephalitis, acute necrotizing hemorrhagic encephalopathy, and acute Guillain–Barré syndrome. Furthermore, SARS-CoV-2 RNA detected in a cerebrospinal fluid specimen of a patient with COVID-19 have provided direct evidence to support the theory of neurotropic involvement of SARS-CoV-2. However, the underlying neurotropic mechanisms of SARS-CoV-2 are yet to be established. SARS-CoV-2 may affect CNS through two direct mechanisms (hematogenous dissemination or neuronal retrograde dissemination) or via indirect routes. The underlying mechanisms require further elucidation in the future.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1007/s00415-020-09929-7
bibo:pmid	32458193
has license	no-cc
sha1sum (hex)	5433f842bc0e8898ca8e9aa20f868aaed1196fb5
schema:url	https://doi.org/10.1007/s00415-020-09929-7
resource representing a document's title	Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms
has PubMed Central identifier	PMC7249973
has PubMed identifier	32458193
schema:publication	J Neurol
resource representing a document's body	covid:5433f842bc0e8898ca8e9aa20f868aaed1196fb5#body_text
is schema:about of	named entity 'Understanding' named entity 'manifestations' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'Coronavirus disease 2019' named entity 'infection' named entity 'CNS' named entity 'viruses' named entity 'ACE2' named entity 'BBB' named entity 'SARS-CoV' named entity '229E' named entity 'ICU' named entity 'SARS-CoV-2' named entity 'mice' named entity 'hyposmia' named entity 'hematogenous' named entity 'SARS-CoV' named entity 'neurotropic' named entity 'CNS' named entity 'neurovirulence' named entity 'SARS-CoV-2' named entity 'smooth muscle cells' named entity 'dizziness' named entity 'coronaviruses' named entity 'tested positive' named entity 'COVID' named entity 'SARS-CoV' named entity 'World Health Organization' named entity 'hypoxia' named entity 'cardiovascular disease' named entity 'encephalitis' named entity 'cardiovascular disease' named entity 'ACE2 receptor' named entity 'neurotropic' named entity 'COVID' named entity 'SARS-COV-2' named entity 'anosmia' named entity 'WHO' named entity 'dizziness' named entity 'NL63' named entity 'SARS-CoV-2' named entity 'encephalopathy' named entity 'risk factors' named entity 'encephalitis' named entity 'hyperplasia' named entity 'organ' named entity 'Olfactory receptor neurons' named entity 'infection' named entity 'COVID-19' named entity 'olfactory bulb' named entity 'ACE2' named entity 'neurological symptoms' named entity 'human coronaviruses' named entity 'clinical symptoms' named entity 'atrophy' named entity 'diabetes' named entity 'cytokine storm' named entity 'subarachnoid hemorrhage' named entity 'fever' named entity 'hyposmia' named entity 'ACE2' named entity 'CSF' named entity 'respiratory tract' named entity 'comorbidities' named entity 'tonic-clonic' named entity 'infection' named entity 'SARS-CoV-2' named entity 'brain tissue' named entity 'encephalopathy' named entity 'infection' named entity 'COVID' named entity 'dyspnea' named entity 'brain tissue' named entity 'COVID' named entity 'SARS-CoV' named entity 'hematogenous'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software